Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print January 9, 2008, doi:10.1212/01.wnl.0000286942.14552.51)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000286942.14552.51v1
70/16_Part_2/1418    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahner, A. D.
Right arrow Articles by Ritz, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahner, A. D.
Right arrow Articles by Ritz, B.
Received May 7, 2007
Accepted August 14, 2007

Statin use and the risk of Parkinson disease

Angelika D. Wahner PhD*, Jeff M. Bronstein MD, PhD, Yvette M. Bordelon MD, PhD, and Beate Ritz MD, PhD

From the Department of Epidemiology (A.D.W., B.R.), UCLA School of Public Health; and the Department of Neurology (J.M.B., Y.M.B.), David Geffen School of Medicine at UCLA and the Greater Los Angeles Veterans Administration Medical Center, Los Angeles, CA.


* To whom correspondence should be addressed. E-mail: awahner{at}ucla.edu.

ABSTRACT

Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).

Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.

Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (≥5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.

Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.